Welcome to our dedicated page for Lexaria Bioscience SEC filings (Ticker: LEXX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Lexaria Bioscience Corp. filings document a Nevada biotechnology company developing and licensing DehydraTECH, its oral drug delivery platform. Registration statements and periodic disclosure materials describe the company's intellectual property licensing segment, research and development activities, B2B initiatives, common stock, warrants, stock options, and risk factors tied to its technology and commercialization model.
Lexaria's 8-K filings record material financing and capital-structure events, including securities purchase agreements, registered direct offerings, concurrent private placement warrants, and the termination of an at-the-market sales agreement. Other filings cover annual meeting voting results, auditor appointment, Nasdaq listing-compliance notices for common stock, and Form 25 records involving warrant listing and registration status.
Lexaria Bioscience Corp. (LEXX) entered into definitive agreements for the immediate exercise of outstanding warrants to purchase 453,969 shares of common stock at a reduced exercise price of $12.92 per share, with closing expected on or about September 9, 2026, subject to customary conditions.
In return for cash exercise of these registered warrants, Lexaria will issue in a private placement new unregistered Series A and Series B warrants for up to 453,969 shares each, both exercisable immediately at $12.67 per share. Series A warrants will expire five years after the effective date of a resale registration statement, while Series B warrants will expire eighteen months after that date.
The transaction is expected to generate approximately $5.9 million in gross proceeds before fees, which, together with a recently received $2.6 million tax rebate from the Australian Tax Office, is expected to be used for working capital and to support operations and research and development programs in 2027. Lexaria highlights its DehydraTECH drug delivery platform and a portfolio of 66 granted patents worldwide.
Lexaria Bioscience Corp. (LEXX) disclosed that its wholly owned Australian subsidiary, Lexaria (AU) Pty Ltd, received an Australian R & D Tax Incentive Credit of AUD$3,666,611.98 on August 28, 2026. The credit relates to research and development costs for its Australian clinical study GLP-1-H24-4.
The funds have been deposited into the subsidiary’s Australian bank account and are intended to be used to pursue additional research and development opportunities in Australia. Lexaria (AU) holds the exclusive rights to use DehydraTECH technology with pharmaceutical GLP-1/GIP and CBD drug products in Australia.
Lexaria Bioscience Corp. reported that on August 17, 2026 it received notice from Nasdaq that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). As a result, the previously requested Nasdaq hearing has been cancelled, and the company’s common stock will continue to be listed and trade on The Nasdaq Capital Market. This removes an overhang related to potential delisting and clarifies that the company currently meets Nasdaq’s bid price standards.
Lexaria Bioscience Corp. reported receiving a Nasdaq Capital Market notification on August 4, 2026 that its common stock is subject to delisting for failing to regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum $1.00 bid price within a 180-day compliance period. The company had already completed a reverse stock split on August 3, 2026, after which its shares have been trading on Nasdaq under CUSIP 52886N604 with a bid price currently above the $1.00 requirement. Lexaria has requested a hearing and paid the related fee, which stays any suspension or delisting while it seeks to demonstrate renewed compliance, and it states that it expects to regain full compliance and maintain continuous Nasdaq trading.
Lexaria Bioscience Corp. will implement a 1-for-15 reverse stock split of its common stock effective at 12:01 am EST on August 3, 2026, aiming to increase its share price and regain compliance with Nasdaq’s $1.00 minimum bid price requirement under the Minimum Price Rule.
The split will reduce issued shares from 24,787,446 to approximately 1,652,518 shares, with fractional shares rounded up, and will proportionally adjust all authorized shares, options, and warrants, including their exercise prices. Authorized shares will decrease from 220,000,000 to 14,666,667, while each shareholder’s percentage ownership remains unchanged.
Lexaria plans to request a Nasdaq hearing in connection with its 180-day compliance period and expects to meet the Minimum Price Rule in mid-August. Post-split, the stock will continue trading on Nasdaq under the symbol LEXX with a new CUSIP number 52886N604. The company also highlights its DehydraTECH drug delivery platform and a portfolio of 66 granted patents.
Lexaria Bioscience Corp. reported a net loss attributable to shareholders of $5.0 million for the nine months ended May 31, 2026, improved from $9.2 million a year earlier, driven mainly by lower research and development spending after completion of a prior Phase 1b trial. Revenue fell sharply to $20,000 from $531,923, reflecting expiry of a key licensing contract and reduced B2B activity as the company pivots toward pharmaceuticals.
Cash was $3.5 million with current liabilities of $0.4 million, yielding working capital of $3.7 million, supported by $6.5 million in net equity proceeds from two registered direct offerings. Management nonetheless states there is substantial doubt about the ability to continue as a going concern beyond the first quarter of fiscal 2027 without additional financing or partnerships.
The company continues to develop its DehydraTECH drug delivery platform, focusing on GLP‑1, GIP and glucagon drugs for diabetes and weight loss, and CBD for hypertension under an active FDA IND. It is running new human and animal GLP‑1 studies and exploring strategic options under an extended material transfer agreement with a pharmaceutical counterparty. Lexaria also discloses it received a Nasdaq notice for failing the $1.00 minimum bid price requirement and may need corporate actions, such as a reverse split, to maintain its listing.
Lexaria Bioscience Corp. reports lower revenue and a narrower loss while highlighting going concern risks. For the six months ended February 28, 2026, revenue fell to $20,000 from $357,923, reflecting the expiration of a key licensing contract and reduced B2B focus. Net loss attributable to shareholders improved to $3.0 million from $5.4 million as research and development spending decreased after completing a major GLP‑1 clinical trial.
Cash rose to $5.1 million with working capital of $5.6 million, largely driven by two equity financings that raised about $6.5 million in net proceeds. Despite this, accumulated deficit reached $66.5 million, and recurring losses and negative cash flows led management to state there is “substantial doubt” about the company’s ability to continue as a going concern over the next year. Management expects current cash to fund operations only through the first quarter of fiscal 2027 and plans to rely on additional equity or partnership funding.
Lexaria Bioscience Corp. director Christopher Bunka reported a bona fide gift of 100,000 common shares back to Lexaria, which were returned to the company’s treasury. This was not an open‑market sale and carried no stated share price.
After the gift, Bunka holds 273,543 common shares directly and 281,912 common shares indirectly through a private holding company as of the reported date. He also retains multiple stock option awards over additional common shares, with exercise prices between 1.0400 and 3.0000 per share and expirations from 2026 through 2030.
Lexaria Bioscience Corp. reported that on February 4, 2026 it received a Nasdaq notice that its common stock no longer meets the Nasdaq Capital Market’s minimum bid price requirement of $1.00 per share. The stock remains listed and continues to trade under the symbol LEXX.
The company has 180 calendar days, until August 3, 2026, for its closing bid price to be at or above $1.00 per share for at least 10 consecutive business days (and up to 20 at Nasdaq’s discretion) to regain compliance. If it does not do so, Lexaria may qualify for an additional 180‑day period if it meets all other initial listing standards and notifies Nasdaq of plans to cure the deficiency, potentially including a reverse stock split.
If Lexaria cannot meet these conditions, Nasdaq may move to delist the stock, and the company would then have the opportunity to appeal. Lexaria states that it intends to actively monitor its share price and evaluate options to address the deficiency, but it notes there is no assurance it will regain or maintain compliance.
Lexaria Bioscience Corp. reported the results of its annual shareholder meeting held on January 27, 2026. A total of 8,380,389 shares, or 37.71% of issued share capital as of December 1, 2025, were represented in person or by proxy.
Shareholders elected all seven director nominees, with approval levels ranging from 73.6% to 96.4%. They also approved the appointment of Malone Bailey LLP as auditors, with 97.0% of votes cast in favor.
In addition, shareholders voted to ratify the lawful actions of the directors for the past year, with 90.0% approval, signaling broad support for the company’s current leadership and governance decisions.